Free Trial

XOMA Royalty (XOMA) 10K Form and Latest SEC Filings 2026

XOMA Royalty logo
$41.76 +0.01 (+0.02%)
As of 01:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest XOMA Royalty SEC Filings & Recent Activity

XOMA Royalty (NASDAQ:XOMA) has submitted 371+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form DEFA14A submitted on May 18, 2026.

Form 4
XOMA Royalty Corp Reports Ownership Change on Apr. 22, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
XOMA Royalty Files Current Report on Apr. 27, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
XOMA Royalty Files Quarterly Report on May. 12, 2026

The 10-Q contains XOMA Royalty's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

XOMA Royalty SEC Filing History

Browse XOMA Royalty's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/18/2026 8:11 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/18/2026 8:13 AM
XOMA Royalty (791908) Filer
Form DEFA14A
05/15/2026 8:03 AM
Woodline Partners LP (1784547) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G
05/12/2026 3:06 PM
XOMA Royalty (791908) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/01/2026 8:15 PM
LIGAND PHARMACEUTICALS INC (886163) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13D
04/30/2026 1:38 PM
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G
04/29/2026 4:43 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13D/A
04/27/2026 6:37 PM
LIGAND PHARMACEUTICALS INC (886163) Filer
XOMA Royalty (791908) Filer
Form DEFA14A
04/27/2026 3:12 PM
BlackRock, Inc. (2012383) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G
04/27/2026 3:01 PM
XOMA Royalty (791908) Filer
Form 8-K/A
04/27/2026 7:16 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/27/2026 7:19 AM
XOMA Royalty (791908) Filer
Form DEFA14A
04/22/2026 3:30 PM
Sitko Bradley (1959809) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:30 PM
Hughes Owen (1575933) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:30 PM
Montano Maricel Perea (2076299) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:30 PM
Trigilio Jeffrey (1838671) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:13 PM
Trigilio Jeffrey (1838671) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 3:30 PM
LIMBER JOSEPH M (1216023) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/30/2026 4:34 PM
XOMA Royalty (791908) Filer
Form DEFA14A
03/30/2026 4:35 PM
XOMA Royalty (791908) Filer
Form ARS
03/27/2026 1:14 PM
VANGUARD GROUP INC (102909) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G/A
03/26/2026 3:30 PM
WYSZOMIERSKI JACK L (1023225) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 5:45 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/17/2026 3:38 PM
Hughes Owen (1575933) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 6:09 PM
Montano Maricel Perea (2076299) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 6:09 PM
Trigilio Jeffrey (1838671) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 6:09 PM
Sitko Bradley (1959809) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 9:05 AM
FMR LLC (315066) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G/A
03/02/2026 5:04 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/12/2026 1:36 PM
MORGAN STANLEY (895421) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G/A
02/09/2026 3:19 PM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/30/2026 4:14 PM
Generation Bio Co. (1733294) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
01/15/2026 3:25 PM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/14/2026 3:30 PM
Trigilio Jeffrey (1838671) Reporting
XOMA Royalty (791908) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/14/2026 3:35 PM
Trigilio Jeffrey (1838671) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 6:58 AM
Generation Bio Co. (1733294) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
01/12/2026 6:00 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2026 3:05 PM
Generation Bio Co. (1733294) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T
12/15/2025 7:36 PM
Generation Bio Co. (1733294) Subject
XOMA Royalty (791908) Filed by
Form SC TO-C
12/05/2025 8:15 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/21/2025 6:50 AM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
Read now. Do not delete. You’ve been warned. (Ad)

Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel

Don’t be left behind. Click here now.
11/21/2025 7:03 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 6:16 AM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
11/12/2025 6:46 AM
XOMA Royalty (791908) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/12/2025 6:46 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 11:22 AM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
10/03/2025 4:24 PM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 4:00 PM
XOMA Royalty (791908) Filer
Form 424B5
10/03/2025 4:03 PM
XOMA Royalty (791908) Filer
Form 424B5
10/02/2025 3:35 PM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
09/26/2025 4:29 PM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/23/2025 4:32 PM
Montano Maricel Perea (2076299) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:32 PM
BURNS THOMAS M. (1638479) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:32 PM
Hughes Owen (1575933) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:32 PM
Sitko Bradley (1959809) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:13 PM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/17/2025 8:10 AM
HilleVax, Inc. (1888012) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
09/12/2025 3:30 PM
Montano Maricel Perea (2076299) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2025 3:07 PM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
09/03/2025 4:15 PM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
08/18/2025 7:23 AM
HilleVax, Inc. (1888012) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T
08/15/2025 7:49 AM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T
08/14/2025 3:10 PM
Montano Maricel Perea (2076299) Reporting
XOMA Royalty (791908) Issuer
Form 3
Initial statement of beneficial ownership of securities  
08/14/2025 3:11 PM
Montano Maricel Perea (2076299) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2025 6:45 AM
XOMA Royalty (791908) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 6:41 AM
XOMA Royalty (791908) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/11/2025 8:15 AM
Turnstone Biologics Corp. (1764974) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T/A
08/06/2025 11:19 AM
FMR LLC (315066) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G/A
08/04/2025 7:05 AM
LAVA Therapeutics NV (1840748) Subject
XOMA Royalty (791908) Filed by
Form SC TO-C
08/04/2025 6:32 AM
HilleVax, Inc. (1888012) Subject
XOMA Royalty (791908) Filed by
Form SC TO-C
07/29/2025 1:54 PM
VANGUARD GROUP INC (102909) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G
07/11/2025 5:05 AM
Turnstone Biologics Corp. (1764974) Subject
XOMA Royalty (791908) Filed by
Form SC TO-T
07/02/2025 3:30 PM
Sitko Bradley (1959809) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 7:00 AM
Turnstone Biologics Corp. (1764974) Subject
XOMA Royalty (791908) Filed by
Form SC TO-C
06/06/2025 3:14 PM
MORGAN STANLEY (895421) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13G/A
05/23/2025 3:46 PM
Kosacz Barbara (1763316) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:47 PM
Franklin Heather L (1436658) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:47 PM
Hernday Natasha (1780547) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:47 PM
PERRY MATTHEW D (1454337) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:47 PM
LIMBER JOSEPH M (1216023) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:48 PM
WYSZOMIERSKI JACK L (1023225) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:48 PM
Kosacz Barbara (1763316) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:11 PM
BURNS THOMAS M. (1638479) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:11 PM
Hughes Owen (1575933) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2025 5:52 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
XOMA Royalty (791908) Subject
Form SCHEDULE 13D/A
05/20/2025 5:56 PM
BIOTECHNOLOGY VALUE FUND II LP (1102444) Reporting
BIOTECHNOLOGY VALUE FUND L P (918923) Reporting
Biotechnology Value Trading Fund OS LP (1660683) Reporting
BVF GP HOLDINGS LLC (1803809) Reporting
BVF I GP LLC (1803805) Reporting
BVF II GP LLC (1803806) Reporting
BVF INC/IL (1056807) Reporting
BVF PARTNERS L P/IL (1055947) Reporting
BVF Partners OS Ltd. (1660684) Reporting
LAMPERT MARK N (1233840) Reporting
XOMA Royalty (791908) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

XOMA Royalty SEC Filings - Frequently Asked Questions

XOMA Royalty (XOMA) has submitted 371+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

XOMA Royalty's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form DEFA14A submitted on May 18, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:XOMA) was last updated on 5/18/2026 by MarketBeat.com Staff.
From Our Partners